The WHO Consolidated Guidelines on Tuberculosis groups all the WHO TB recommendations in one document. The guidelines are complemented by matching modules of a consolidated operational handbook. The operational handbook provides practical advice on how to put in place the recommendations at the scale needed to achieve national and global impact.1 WHO consolidated guidelines on tuberculosis Module 4: Treatment - Drug-resistant tuberculosis treatment, 2020, WHO, https://pubmed.ncbi.nlm.nih.gov/32603040/
Module 1: Prevention
Tuberculosis preventive treatment.2WHO consolidated guidelines on tuberculosis: module 1: prevention: tuberculosis preventive treatment, 2020, WHO, https://www.who.int/publications/i/item/who-consolidated-guidelines-on-tuberculosis-module-1-prevention-tuberculosis-preventive-treatment
There are 18 recommendations in the 2020 update. The main changes include conditional recommendations for a 1 month daily rifapentine and isoniazid regimen, and a 4 month daily rifampicin regimen as alternative treatment options.
Module 2: Screening
Systematic screening for tuberculosis disease. 3WHO consolidated guidelines on tuberculosis: Module 2 : Screening - Systematic screening for tuberculosis disease, 2021, WHO, https://www.who.int/publications/i/item/9789240022676/
This document is an update of the 2013 guidelines. A set of 17 new and revised recommendations for screening for TB disease have been developed.
Module 3: Diagnosis
Rapid diagnostics for tuberculosis detection.4WHO consolidated guidelines on tuberculosis Module 3: Diagnosis - Rapid diagnostics for tuberculosis detection, 2020, WHO, https://www.who.int/publications/i/item/who-consolidated-guidelines-on-tuberculosis-module-3-diagnosis---rapid-diagnostics-for-tuberculosis-detection
This document consolidates five guidelines developed by WHO between 2016 and 2020. A range of new diagnostic technologies have been endorsed by WHO between 2010 and 2020. This document provides background, justification and recommendations on these technologies. It also includes new recommendations on molecular assays intended as initial tests for the diagnosis of pulmonary and extrapulmonary TB and rifampicin resistance in adults and children.
Module 4: Treatment
Drug resistant tuberculosis treatment.5WHO consolidated guidelines on Tuberculosis Module 4: Treatment - Drug-Resistant Tuberculosis Treatment, 2020, WHO, https://www.who.int/publications/i/item/9789240007048
This second module includes a comprehensive set of WHO recommendations for the treatment and care of people with drug resistant TB. The document includes two new recommendations. The first is on the composition of shorter regimens and the second is on the use of the BPaL regimen (i.e. bedaquiline, pretomanid and linezolid).
This page was last updated in May 2021.
Author Annabel Kanabus
If you have found this page useful please tell other people about TBFacts.org and if you have a website please link to us at https://tbfacts.org/who-tb-guidelines/.